{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:12:38Z","timestamp":1786705958529,"version":"build-2736575974"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>\n            Objective\u2003This study aimed to analyze the effect of pravastatin on angiogenic factors, feto\u2013maternal Doppler findings and pregnancy outcomes in women with early-onset fetal growth restriction (FGR) treated with pravastatin compared with nontreated controls.<\/jats:p><jats:p>\n            Study Design\u2003This was a pilot study conducted between March 2016 and September 2017. Women with single pregnancies and FGR diagnosed at\u2009\u2264\u200928 weeks of gestation were offered 40\u2009mg of pravastatin daily. Doppler progression, soluble fms-like tyrosine kinase 1 (sFlt-1)\/placental growth factor (PlGF) values, and pregnancy outcomes were assessed and compared with consecutive historical controls. Controls were matched to treated women for gestational age, maternal characteristics, maternal and obstetric history, Doppler severity classification, and angiogenic factors at diagnosis. The sFlt-1\/PlGF was measured in maternal serum at two different times: before pravastatin was started (ratio M0) and during pravastatin treatment (ratio M1). Doppler severity was classified into four categories: normal, mild, moderate, and severe.<\/jats:p><jats:p>\n            Results\u2003A total of 38 women were enrolled in this study. No differences were observed in baseline characteristics between groups. However, when compared with the ratio M0, M1 was increased by a median (interquartile range) of 67.0 (\u221234.8 to 197.3) in the control group but decreased by a median (interquartile range) of \u221210.1 (\u221253.1 to \u22120.07) in the pravastatin treated group (p\u2009&lt;\u20090.001). No significant differences were observed in Doppler progression throughout pregnancy. Median interval from diagnosis to delivery was extended by 16.5 days, the median newborn birthweight was increased from 1,040 to 1,300\u2009g, and the number of women with preeclampsia decreased from 9 (47.4%) to 6 (31.6%) in treated women; however, these trends were not statistically significant.<\/jats:p><jats:p>\n            Conclusion\u2003In women with early-onset FGR, treatment with pravastatin 40\u2009mg daily was associated with significant improvement in the angiogenic profile. Additionally, median pregnancy duration and median birthweight increased and the incidence of PE was reduced in treated women. Nevertheless, since this pilot study was underpowered, none of these differences were statistically significant.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/s-0040-1713651","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T22:39:56Z","timestamp":1593729596000},"page":"1472-1479","source":"Crossref","is-referenced-by-count":19,"title":["Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study"],"prefix":"10.1055","volume":"38","author":[{"given":"Elena","family":"Carreras","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Alijotas-Reig","sequence":"first","affiliation":[{"name":"Department of Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-3833","authenticated-orcid":false,"given":"Manel","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ferrer-Oliveras","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Bonacina","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Manau","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Rodo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Maternal Fetal Medicine Unit, Hospital Universitari Vall d'Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000357592","article-title":"Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol","volume":"36","author":"F Figueras","year":"2014","journal-title":"Fetal Diagn Ther"},{"issue":"16","key":"ref2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199904223401603","article-title":"Birth weight in relation to morbidity and mortality among newborn infants","volume":"340","author":"D D McIntire","year":"1999","journal-title":"N Engl J Med"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0002-9378(75)90011-3","article-title":"The placental pathology of small-for-gestational age infants","volume":"121","author":"G Altshuler","year":"1975","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000359969","article-title":"Placental pathology in early-onset and late-onset fetal growth restriction","volume":"36","author":"W Mifsud","year":"2014","journal-title":"Fetal Diagn Ther"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"R J Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/uog.5184","article-title":"Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction","volume":"31","author":"F Crispi","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","article-title":"A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate","volume":"21","author":"R Romero","year":"2008","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/uog.18894","article-title":"Longitudinal change of sFlt-1\/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction","volume":"52","author":"I Herraiz","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/AOG.0000000000002209","article-title":"Early second-trimester fetal growth restriction and adverse perinatal outcomes","volume":"130","author":"L A Temming","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jri.2017.08.005","article-title":"Comparison of risk factors and perinatal outcomes in early onset and late onset preeclampsia: a cohort based study in Reunion Island","volume":"123","author":"S Iacobelli","year":"2017","journal-title":"J Reprod Immunol"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11632010-000000000-00000","article-title":"Statins and pregnancy: between supposed risks and theoretical benefits","volume":"72","author":"E Lecarpentier","year":"2012","journal-title":"Drugs"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1172\/JCI89137","article-title":"Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome","volume":"126","author":"M M Costantine","year":"2016","journal-title":"J Clin Invest"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.placenta.2013.05.002","article-title":"The transfer of pravastatin in the dually perfused human placenta","volume":"34","author":"J Zarek","year":"2013","journal-title":"Placenta"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"e0172174","DOI":"10.1371\/journal.pone.0172174","article-title":"The effects of pravastatin on the normal human placenta: lessons from ex-vivo models","volume":"12","author":"A Balan","year":"2017","journal-title":"PLoS One"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia","volume":"66","author":"F C Brownfoot","year":"2015","journal-title":"Hypertension"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"E Lefkou","year":"2016","journal-title":"J Clin Invest"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejogrb.2006.12.015","article-title":"Customized birthweight standards for a Spanish population","volume":"136","author":"F Figueras","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/uog.902","article-title":"Relationship between placental blood flow resistance and precordial venous Doppler indices","volume":"22","author":"A A Baschat","year":"2003","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: a Delphi procedure","volume":"48","author":"S J Gordijn","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/AOG.0b013e3181841395","article-title":"The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines","volume":"112","author":"G A Macones","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/pd.4412","article-title":"Stage-based approach to the management of fetal growth restriction","volume":"34","author":"F Figueras","year":"2014","journal-title":"Prenat Diagn"},{"issue":"05","key":"ref22","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy","volume":"122","author":"American College of Obstetricians and Gynecologists","year":"2013","journal-title":"Obstet Gynecol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"S P Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/hr.2010.92","article-title":"Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia","volume":"33","author":"A Molvarec","year":"2010","journal-title":"Hypertens Res"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"H Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bpobgyn.2018.02.009","article-title":"Planning management and delivery of the growth-restricted fetus","volume":"49","author":"A A Baschat","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/uog.13190","article-title":"Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE)","volume":"42","author":"C Lees","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vph.2018.06.001","article-title":"Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect","volume":"110","author":"A Jurisic","year":"2018","journal-title":"Vascul Pharmacol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bcpt.13149","article-title":"Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction","volume":"124","author":"J S Chimini","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1073\/pnas.1520356113","article-title":"Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess","volume":"113","author":"C S Wyrwoll","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1713651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:49:26Z","timestamp":1637624966000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1713651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,11,22]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1713651","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}